Publications en collaboration avec des chercheurs de Leiden University Medical Center (92)

2024

  1. CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer

    Molecular Therapy Nucleic Acids, Vol. 35, Núm. 2

  2. Corrigendum to “European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO” [Eur J Surg Oncol 50 (1) (January 2024) 107292] (European Journal of Surgical Oncology (2024) 50(1), (S0748798323009307), (10.1016/j.ejso.2023.107292))

    European Journal of Surgical Oncology

  3. European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO

    European Journal of Surgical Oncology, Vol. 50, Núm. 1

  4. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 9, pp. 2706-2732

  5. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines

    European Journal of Nuclear Medicine and Molecular Imaging

  6. Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines

    Breast, Vol. 78

  7. The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

    Molecular Therapy Oncology, Vol. 32, Núm. 2

  8. The role of time in involving patients with cancer in treatment decision making: A scoping review

    Patient Education and Counseling, Vol. 125

2023

  1. COVID-19 risk, course and outcome in people with mental disorders: a systematic review and meta-analyses

    Epidemiology and psychiatric sciences, Vol. 32, pp. e61

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy

    European Journal of Cancer, Vol. 181, pp. 79-91

  4. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

    Neuro-oncology, Vol. 25, Núm. 1, pp. 37-53

  5. Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi

    Molecular Therapy Nucleic Acids, Vol. 34

  6. SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: Systematic review with frequentist and Bayesian meta-analyses

    British Journal of Psychiatry, Vol. 223, Núm. 2, pp. 348-361

  7. Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomas

    Clinical Epigenetics, Vol. 15, Núm. 1

  8. The MooDFooD randomized controlled trial: the data and its implications for the theory

    Psychological Medicine

2022

  1. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33

  2. Correction: Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results From the INSPIRE Registry (Annals of Surgical Oncology, (2022), 29, 3, (1722-1734), 10.1245/s10434-021-10930-1)

    Annals of Surgical Oncology

  3. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494

  4. Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score

    Thrombosis and Haemostasis, Vol. 122, Núm. 5, pp. 818-829